Berylson Capital Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Berylson Capital Partners’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-228,000	Closed	-$1.53M	–	27
2023 Q2	$1.53M	Sell	228,000 -42,000	-16%	-$312K	4.33%	9
2023 Q1	$2.38M	Sell	270,000 -19,726	-7%	-$174K	6%	7
2022 Q4	$2.21M	Hold	289,726	–	–	6.45%	7
2022 Q3	$2.06M	Buy	289,726 +100,000	+53%	+$942K	3.41%	15
2022 Q2	$1.53M	Buy	+189,726	New	+$1.67M	4.15%	13
2021 Q4	–	Sell	-61,000	Closed	-$2.07M	–	26
2021 Q3	$2.07M	Sell	61,000 -185,200	-75%	-$6.7M	0.96%	25
2021 Q2	$10.1M	Sell	246,200 -69,800	-22%	-$2.71M	2.23%	16
2021 Q1	$12.7M	Buy	+316,000	New	+$17.1M	3.1%	11

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AAP

Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Berylson Capital Partners's ADPT Position: Q3 2023 in Review

Berylson Capital Partners sold out of Adaptive Biotechnologies (ADPT) in Q3 2023, closing a stake of 228,000 shares — an estimated $1.53M sold.

Berylson Capital Partners first reported a position in ADPT in Q1 2021 and held it in 8 quarters. The position peaked at $12.7M in Q1 2021. 190 funds tracked by Wall St. Rank hold ADPT as of Q3 2023.

Berylson Capital Partners reported no remaining Adaptive Biotechnologies position as of Q3 2023 after selling out during the quarter.
Berylson Capital Partners sold 228,000 Adaptive Biotechnologies shares in Q3 2023, an estimated $1.53M.
Berylson Capital Partners first reported a position in Adaptive Biotechnologies in Q1 2021 and held it in 8 quarters.
Berylson Capital Partners's Adaptive Biotechnologies position peaked at $12.7M in Q1 2021.
190 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2023.

Based on Berylson Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.